Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California. more
Time Frame | ANAB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -27.23% | -3.72% | -0.05% |
1-Month Return | -11.81% | -1.85% | 2.75% |
3-Month Return | -57% | -11.4% | 7.4% |
6-Month Return | -28.79% | -4.41% | 10.47% |
1-Year Return | -15.27% | 4.13% | 27.57% |
3-Year Return | -52.85% | 0.3% | 29.56% |
5-Year Return | 1.52% | 36.62% | 89.3% |
10-Year Return | -2.06% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 8.00M | 75.00M | 63.17M | 10.29M | 17.16M | [{"date":"2019-12-31","value":10.67,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.23,"profit":true},{"date":"2022-12-31","value":13.72,"profit":true},{"date":"2023-12-31","value":22.88,"profit":true}] |
Cost of Revenue | 99.34M | 80.03M | 98.50M | 2.33M | 2.38M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":80.56,"profit":true},{"date":"2021-12-31","value":99.15,"profit":true},{"date":"2022-12-31","value":2.35,"profit":true},{"date":"2023-12-31","value":2.39,"profit":true}] |
Gross Profit | (91.34M) | (5.03M) | (35.32M) | 7.95M | 14.78M | [{"date":"2019-12-31","value":-617.94,"profit":false},{"date":"2020-12-31","value":-34,"profit":false},{"date":"2021-12-31","value":-238.96,"profit":false},{"date":"2022-12-31","value":53.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (1141.72%) | (6.70%) | (55.91%) | 77.30% | 86.15% | [{"date":"2019-12-31","value":-1325.25,"profit":false},{"date":"2020-12-31","value":-7.78,"profit":false},{"date":"2021-12-31","value":-64.9,"profit":false},{"date":"2022-12-31","value":89.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 115.43M | 98.88M | 119.99M | 125.44M | 181.57M | [{"date":"2019-12-31","value":63.58,"profit":true},{"date":"2020-12-31","value":54.46,"profit":true},{"date":"2021-12-31","value":66.08,"profit":true},{"date":"2022-12-31","value":69.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (107.43M) | (23.88M) | (56.81M) | (115.15M) | (164.41M) | [{"date":"2019-12-31","value":-10743200000,"profit":false},{"date":"2020-12-31","value":-2387900000,"profit":false},{"date":"2021-12-31","value":-5681400000,"profit":false},{"date":"2022-12-31","value":-11515400000,"profit":false},{"date":"2023-12-31","value":-16441100000,"profit":false}] |
Total Non-Operating Income/Expense | 19.89M | 7.91M | (2.00M) | (27.10M) | 1.24M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.76,"profit":true},{"date":"2021-12-31","value":-10.06,"profit":false},{"date":"2022-12-31","value":-136.29,"profit":false},{"date":"2023-12-31","value":6.26,"profit":true}] |
Pre-Tax Income | (97.49M) | (19.93M) | (57.80M) | (128.70M) | (163.62M) | [{"date":"2019-12-31","value":-9748800000,"profit":false},{"date":"2020-12-31","value":-1993100000,"profit":false},{"date":"2021-12-31","value":-5779600000,"profit":false},{"date":"2022-12-31","value":-12870000000,"profit":false},{"date":"2023-12-31","value":-16362300000,"profit":false}] |
Income Taxes | (152.00K) | (11.00K) | (603.00K) | 24.00K | (4.00K) | [{"date":"2019-12-31","value":-633.33,"profit":false},{"date":"2020-12-31","value":-45.83,"profit":false},{"date":"2021-12-31","value":-2512.5,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-16.67,"profit":false}] |
Income After Taxes | (97.34M) | (19.92M) | (57.19M) | (128.72M) | (163.62M) | [{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1992000000,"profit":false},{"date":"2021-12-31","value":-5719300000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-16361900000,"profit":false}] |
Income From Continuous Operations | (97.34M) | (19.93M) | (57.80M) | (128.72M) | (147.82M) | [{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1993100000,"profit":false},{"date":"2021-12-31","value":-5779600000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-14782100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (97.34M) | (19.92M) | (57.19M) | (128.72M) | (163.62M) | [{"date":"2019-12-31","value":-9733600000,"profit":false},{"date":"2020-12-31","value":-1992000000,"profit":false},{"date":"2021-12-31","value":-5719300000,"profit":false},{"date":"2022-12-31","value":-12872400000,"profit":false},{"date":"2023-12-31","value":-16361900000,"profit":false}] |
EPS (Diluted) | (3.61) | (0.76) | (2.05) | (4.57) | (6.08) | [{"date":"2019-12-31","value":-361,"profit":false},{"date":"2020-12-31","value":-76,"profit":false},{"date":"2021-12-31","value":-205,"profit":false},{"date":"2022-12-31","value":-457,"profit":false},{"date":"2023-12-31","value":-608,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ANAB | |
---|---|
Cash Ratio | 9.80 |
Current Ratio | 10.23 |
Quick Ratio | 10.50 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ANAB | |
---|---|
ROA (LTM) | -17.85% |
ROE (LTM) | -161.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ANAB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.83 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.17 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ANAB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 8.30 |
P/B | 5.62 |
Price/FCF | NM |
EV/R | 1.06 |
EV/Ebitda | NM |
PEG | NM |
AnaptysBio Inc (ANAB) share price today is $16.65
Yes, Indians can buy shares of AnaptysBio Inc (ANAB) on Vested. To buy AnaptysBio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ANAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AnaptysBio Inc (ANAB) via the Vested app. You can start investing in AnaptysBio Inc (ANAB) with a minimum investment of $1.
You can invest in shares of AnaptysBio Inc (ANAB) via Vested in three simple steps:
The 52-week high price of AnaptysBio Inc (ANAB) is $41.31. The 52-week low price of AnaptysBio Inc (ANAB) is $14.2.
The price-to-earnings (P/E) ratio of AnaptysBio Inc (ANAB) is
The price-to-book (P/B) ratio of AnaptysBio Inc (ANAB) is 5.62
The dividend yield of AnaptysBio Inc (ANAB) is 0.00%
The market capitalization of AnaptysBio Inc (ANAB) is $474.38M
The stock symbol (or ticker) of AnaptysBio Inc is ANAB